{
    "clinical_study": {
        "@rank": "163165", 
        "arm_group": {
            "arm_group_label": "idarubicin", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "R-CHOP with doxorubicin is the standard first line treatment of high grade non-Hodgkin's\n      lymphoma. In order to avoid central venous system insertion and reduce hospitalization time\n      in elderly patients, we developed an oral chemotherapy treatment:  \" OROCIEP\"trial.\n\n      Nineteen patients were enrolled and 127 chemotherapy cycles were available for toxicities.\n      The estimated two-years overall survival was 74%. The main haematological toxicity was\n      neutropenia.\n\n      This study is still ongoing to confirm recommended dose of oral anthracycline."
        }, 
        "brief_title": "Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma", 
        "condition": "High Grade Lymphomas CD20 +", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  CD20-positive diffuse large B-cell lymphoma.WHO classification (55)\n\n          -  Written informed consent\n\n          -  Age > 65 and < 80 years\n\n          -  Performance status (ECOG) <3\n\n          -  measurable disease\n\n          -  Serology  HIV negative, Hepatites B, Hepatites C negative\n\n        Exclusion Criteria:\n\n          -  Serology HIV positive, Hepatite B positive, Hepatite C positive\n\n          -  Cardiac failure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "65 Years"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958996", 
            "org_study_id": "OROCIEP"
        }, 
        "intervention": {
            "arm_group_label": "idarubicin", 
            "intervention_name": "idarubicin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Idarubicin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 8, 2013", 
        "location": {
            "contact": {
                "email": "vicent.delwail@chu-poitiers.fr", 
                "last_name": "Vincent DELWAIL, MD", 
                "phone": "0033 5 49 44 45 41"
            }, 
            "facility": {
                "address": {
                    "city": "Poitiers", 
                    "country": "France", 
                    "zip": "86000"
                }, 
                "name": "CHU de Poitiers"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "overall_contact": {
            "email": "vincent.delwail@chu-poitiers.fr", 
            "last_name": "Vincent DELWAIL, MD", 
            "phone": "0033 5 49 44 45 41"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose of idarubicin", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Remission rate after 4 cycles and 8 cycles", 
            "time_frame": "9 months"
        }, 
        "source": "Poitiers University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Poitiers University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}